Mathematic modelling of fibrinolysis

Pre and perioperative factors modulate fibrinolysis in arthroplasty patients

Cellular and mechanical modulators of fibrin structure

Platelets, NETs and Immunity

Mechanisms by which DNA, histones and NETs stabilise clots

Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots

Genetics of thrombosis

Non-coding RNAs – novel therapeutic targets in cardiovascular disease

Antithrombotic therapy in cardiovascular patients

Controversies in the treatment of pulmonary embolism

Novel oral anticoagulants and anti F-XI agents

Antithrombotic therapy in cardiovascular patients

Controversies in the diagnosis of pulmonary embolism

Novelties in the treatment of von Willebrand disease

NOACs in the treatment of pulmonary embolism

Impact of incidental MI on future risk on venous thromboembolism (Tromso study)

ISTH Congress

Cancer-associated thrombosis and LMWH biosimilars

The RE-VERSE AD trial: Idarucizumab reverses the anticoagulant effects of dabigatran

Translating the results of the NOAC trials into real-life setting

Real-life experience with the NOACs

The burden of thrombosis and the revolution in its treatment

Overview of the use of NOACs

Opening vessels: From fibrinolysis to interventions

Perioperative Management of Dabigatran: A Prospective Cohort Study